

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
203168Orig1s000

SUMMARY REVIEW

NDA 203168 Prolensa (bromfenac ophthalmic solution) 0.07%

Indication: For the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery

Summary Review for Regulatory Action

Date	See electronic stamp date
From	Renata Albrecht, MD Division of Transplant and Ophthalmology Products
Subject	Division Director Summary Review
BLA Number	NDA 203168
Related IND	IND 60295
Related NDA	NDA 21664, NDA 20535
Review type	Standard
Applicant Name	Bausch & Lomb, previously ISTA
Date of Submission	June 5, 2012
Date of Receipt	June 7, 2012
PDUFA Goal Date	April 7, 2013
Proprietary Name / Established (USAN) Name	Prolensa bromfenac
Formulation Concentration Dosing Regimen	Topical ophthalmic solution 0.07% One drop in the affected eye one time daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 14 days of the post-operative period.
Therapeutic Class Proposed Indication	Nonsteroidal anti-inflammatory agent For the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery
Action for NME	<i>Approval</i>

NDA 203168 Prolensa (bromfenac ophthalmic solution) 0.07%

Indication: For the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery

Material Reviewed/Consulted	Names of discipline reviewers
OND Action Package, including:	
Medical Officer Review	Bill Boyd 3/20/2013
CDTL Review	Bill Boyd 4/5/2013
Deputy Director Review	Wiley Chambers 4/5/2013
Statistical Review	Abel Eshete, Yan Wang 3/4/2013
Team Leader Review	Yan Wang, Daphne Lin 4/4/2013
Pharmacology/Toxicology Review	Robeena Aziz, Lori Kotch 3/4/2013
Clinical Pharmacology Review	Yoriko Hayigaya, Philip Colangelo 2/19/2013
ONDQA CMC Review	Rao Kambhampati, Rapti Madurawe 2/26/2013, 4/4/2013 Rapti Madurawe 4/5/2013
Quality Microbiology Review	Stephen Langille, Bryan Riley 1/22/2013
OSI/DG CPC	Kassa Ayalew, Susan Leibenhaut, Susan Thompson 2/4/2013, 2/20/2013
OSE/DMEPA Proprietary Name Letter Final Review	Jung Lee, Zachary Oleszczuk, Carol Holquist 11/7/2012 Carol Holquist 11/9/2012 Jung Lee, Jamie Wilkins Parker 3/4/2013
OSE/DMEPA Label, Labeling and Packaging Review	Jung Lee, Jamie Wilkins Parker, Carol Holquist 2/8/2013
OPDP/DPDP Review	Christine Corser 3/20/2013
Pediatric Review Committee	This application did not trigger PREA

OND=Office of New Drugs

CDTL=Cross-Discipline Team Leader

ONDQA=Office of New Drug Quality Assessment

OSI/DG CPC=Office of Scientific Investigations/Division of Good Clinical Practice Compliance
(formerly Division of Scientific Investigation (DSI))

OSE=Office of Surveillance and Epidemiology

OMEARM=Office of Medication Error Prevention and Risk Management

DMEPA=Division of Medication Error Prevention and Analysis

OPDP/DPDP=Office of Prescription Drug Promotion/Division of Professional Drug Promotion;
formerly, DDMAC=Division of Drug Marketing, Advertising and Communication

Table of Contents:

Table of Contents:	3
1. Summary and Recommendations	4
1.1 Deficiencies	5
1.2 Post-Marketing Studies:	5
1.3 Other Issues	5
2. Background	5
2.1 Application History	5
3. CMC/Product Quality Microbiology	6
4. Nonclinical Pharmacology/Toxicology	9
5. Clinical Pharmacology/Biopharmaceutics	10
6. Clinical Microbiology/Immunology	10
7. Clinical/Statistical-Efficacy	10
7.1 Phase 3 clinical trials	10
8. Safety	14
8.1 Post Marketing Experience	18
9. Advisory Committee Meeting	18
10. Pediatrics	18
11. Other Relevant Regulatory Issues	18
11.1 Compliance Inspection - Facilities	18
11.2 Office of Scientific Investigation (OSI) Audits	19
11.3 Debarment Certification	19
11.4 Financial Disclosure	19
11.5 Other Regulatory Issues	19
12. Labeling	19
13. Decision/Action/Risk Benefit Assessment	19
13.1 Regulatory Action	19
13.2 Risk Benefit Assessment	20
13.3 Recommendation for other Postmarketing Requirements and Commitments	20

1. Summary and Recommendations

Bromfenac ophthalmic solution, 0.07% has been shown to be effective and safe for the treatment of pain and inflammation associated with cataract surgery based on two Phase 3 trials showing superiority of the product to vehicle. The treatment regimen evaluated in these trials and recommended for approval is one drop in the affected eye one time daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 14 days of the post-operative period.

Key Efficacy Results of Phase 3 Studies in Prolensa NDA (ITT Population) Proportion of Subjects with Cleared Ocular Inflammation (0 cell and no flare)

Study	Visit	Bromfenac 0.07%	Vehicle	Difference (%) (Asymptotic 95% CI)
Study 1	Day 8	27/112 (24.1%)	7/108 (6.5%)	17.6 (8.4, 26.8)
	Day 15	51/112 (45.5%)	14/108 (13.0%)	32.5 (21.4, 43.8)
Study 2	Day 8	33/110 (30.0%)	14/110 (12.7%)	17.3 (6.7, 27.9)
	Day 15	50/110 (45.4%)	30/110 (27.3%)	18.2 (5.7, 30.7)
Proportion of Subjects Who Were Pain Free				
Study 1	Day 1	91/112 (81.3%)	47/108 (43.5%)	37.7 (25.9, 49.6)
Study 2	Day 1	84/110 (76.4%)	61/110 (55.5%)	20.9 (8.7, 33.1)

The safety of the 0.07% bromfenac formulation was evaluated in 222 patients treated with this product and compared to 218 patients who received vehicle. This represents a new concentration of bromfenac. The safety of bromfenac 0.09% given twice daily (Xibrom) and once daily (Bromday) was evaluated in NDA 21-664 for the same indication(s).

The labeling will include information on adverse reactions in these trials, and other safety information. The Warnings and Precautions includes information that the product contains sodium sulfite and may cause allergic reactions in susceptible people, NSAIDs may slow or delay healing, there is a potential cross-sensitivity with aspirin, increase bleeding time, and potential for keratitis and corneal erosion, ulceration and perforation. Common adverse reactions after cataract surgery associated with Prolensa use included anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and blurred vision. These adverse reactions were reported in 3 to 8% of patients.

All reviewers recommend approval. OSI recommends that clinical site data are considered reliable. As summarized in the CMC review, OC recommends that manufacturing facilities are

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.